100 citations
,
July 2006 in “British Journal of Dermatology” Triamcinolone acetonide injections help hair regrow quickly in mild alopecia but not in severe cases.
9 citations
,
March 2008 in “British Journal of Dermatology” Efalizumab can cause unexpected excessive hair growth.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
60 citations
,
October 2009 in “PubMed” Intralesional steroid injections are safe and effective for treating severe alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
January 2015 in “Journal of evolution of medical and dental sciences” Topical tacrolimus is effective and safe for treating alopecia areata.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
November 2025 in “International Journal of Research in Medical Sciences” Titagen® improves skin, hair, nail health, and reduces osteoarthritis symptoms safely.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
January 2013 in “Biology of blood and marrow transplantation” Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.
Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
29 citations
,
March 1983 in “Journal of The American Academy of Dermatology” New treatments for psoriasis have improved effectiveness and may reduce long-term side effects when combined with standard therapies.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
A 29-year-old woman with symptoms of both lupus and rheumatoid arthritis improved with specific medications.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
1 citations
,
April 2019 in “Acta Medica Philippina” Azathioprine may help treat severe alopecia areata, but more research is needed.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
November 2022 in “Indian Journal of Dermatology” Azole antifungals can cause skin reactions like EAC, requiring careful management.
8 citations
,
June 2024 in “Pharmaceutics” PEA-ENL improves skin delivery and reduces inflammation without side effects.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.